Q-omics provides the consensus-scored RIMS3 profile across patient tissues and cancer cell-line models. RIMS3 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RIMS3 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, RIMS3 RNA expression shows 22,703 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, COAD, and GBM as cancer lineages where RIMS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMS3 survival associations across molecular data types. RIMS3 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (6) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMS3 RNA expression–survival associations across cancer types. High RIMS3 expression shows unfavorable associations in LIHC, ACC, LUSC, THCA and UCEC, but favorable associations in UCS. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RIMS3 RNA expression.
This table summarizes RIMS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RIMS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMS3 shows lower tumor expression in COAD, KIRC, THCA, KICH and LUAD and higher tumor expression in LIHC. The COAD box plot shows higher RIMS3 RNA expression in normal versus tumor tissue (log2 FC = −1.248, t-test p < 0.001).
This table shows molecular features associated with RIMS3 in patient tissues and cancer cell lines. In patient samples, RIMS3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
